Mechanistically, CG-806 triggers G1 phase arrest in FLT3-mutated AML cells by predominantly targeting FLT3 and BTK, and G2/M phase arrest in FLT3-WT AML cells by predominantly targeting AURK. The gene discussed is BTK; the disease is acute myeloid leukemia.